COVRE ALESSIA

Alessia
Covre
Ricercatore Legge 240/10 - tempo determinato

Teaching activities

Completion accademic year: 2021/2022

Completion accademic year: 2020/2021

Completion accademic year: 2019/2020

Research

Ultime pubblicazioni:

  • Noviello, T.M.R., Di Giacomo, A.M., Caruso, F.P., Covre, A., Mortarini, R., Scala, G., et al. (2023). Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. NATURE COMMUNICATIONS, 14(1), 5914 [10.1038/s41467-023-40994-4]. - view more
  • Sabato, C., Noviello, T.M.R., Covre, A., Coral, S., Caruso, F.P., Besharat, Z.M., et al. (2022). A novel microRNA signature for the detection of melanoma by liquid biopsy. JOURNAL OF TRANSLATIONAL MEDICINE, 20(1), 1-14 [10.1186/s12967-022-03668-1]. - view more
  • Montico, B., Giurato, G., Pecoraro, G., Salvati, A., Covre, A., Colizzi, F., et al. (2022). The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma. MOLECULAR ONCOLOGY, 16(3), 565-593 [10.1002/1878-0261.13034]. - view more
  • Anichini, A., Molla, A., Nicolini, G., Perotti, V.E., Sgambelluri, F., Covre, A., et al. (2022). Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 41(1), 1-15 [10.1186/s13046-022-02529-5]. - view more
  • Calabro, L., Rossi, G., Morra, A., Rosati, C., Cutaia, O., Daffina, M.G., et al. (2021). Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. THE LANCET RESPIRATORY MEDICINE, 9(9), 969-976 [10.1016/S2213-2600(21)00043-6]. - view more